NasdaqGM:TVTXBiotechs
FDA’s First FSGS Therapy Approval for FILSPARI Could Be A Game Changer For Travere Therapeutics (TVTX)
Earlier this month, Travere Therapeutics announced that the FDA approved FILSPARI (sparsentan) to reduce proteinuria in adults and children aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only approved therapy for this rare kidney disease.
This approval, backed by the large Phase 3 DUPLEX Study and aligned with KDIGO guidelines, extends FILSPARI’s reach beyond IgA nephropathy into a second rare kidney indication and expands...